Physician profile
Daniel Langley
NPI 1659361541
$2,935.83
in general payments reported to CMS, 2019-2025
21 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $510 · 2021: $396 · 2022: $513 · 2023: $326 · 2024: $318 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $469.57 | 2019-2021 | |
| Abbvie INC. | $462.17 | 2022-2025 | |
| Alcon Vision LLC | $461.18 | 2020-2025 | Clareon Panoptix Pro, Ngenuity, Luxor |
| Biotissue Holdings INC. | $430.72 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $261.66 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $184.88 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $100.61 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $92.99 | 2020 | |
| Glaukos Corporation | $74.28 | 2019-2020 | |
| Amgen INC. | $60.66 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $55.08 | 2019 | |
| Shire North American Group INC | $52.58 | 2019 | |
| Horizon Therapeutics Plc | $52.45 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.26 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $26.59 | 2022-2023 | Omidria, Rayone Spheric, Rayone Emv |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $25.24 | 2022 | |
| Astellas Pharma US INC | $21.30 | 2025 | Izervay |
| Kala Pharmaceuticals, INC. | $18.11 | 2020 | |
| Ocular Therapeutix, INC. | $17.84 | 2021 | |
| Harrow Eye, LLC | $15.07 | 2025 | |
| The Cameron-Ehlen Group, INC. | $3.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Langley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.